Globally, immunization has proven to be the gateway to health for millions, and continued investment in vaccine development provides a measureable return in reducing the burden of disease and safeguarding human development. Today, more than ever, vaccine technology remains at the forefront of the confrontation against infectious disease. Cambridge Healthtech Institute’s Eleventh Annual Immunization and Vaccine Summit will cover a range of topics in this evolving field, including the latest advancements and applications of vaccine technologies, development of effective vaccine adjuvants, and progress in DNA- and RNA-based vaccines.
Conference Programs Include:
Carl Alving, Chief, Adjuvant & Antigen Research, Walter Reed Army Institute of Research
Peter Andersen, Professor, Statens Serum Institute
Simon Delagrave, Senior Director & Head, Virology Research, Sanofi Pasteur
Laurent Humeau, Vice President, R&D, Inovio Pharmaceuticals
Nicholas Jackson, Vice President, Head of Research, Sanofi Pasteur
Derek O’Hagan, Global Head, Vaccine Chemistry & Formulation, GlaxoSmithKline Vaccines
Jeffrey Ulmer, Head, Preclinical R&D, GlaxoSmithKline Vaccines
|For more details on the conference, please contact:
Senior Associate Producer
T: (+1) 781-972-5436
|For exhibit & sponsorship opportunities, please contact:
Business Development Manager
T: (+1) 781-972-1349
Each year, ImVacS brings vaccine professionals together from around the world to discuss the crucial issues surrounding vaccine development. Along with presenting a snapshot of where vaccines stand today, the meeting also provides an important venue for networking, information exchange, and establishing collaborations.
The “Novel Vaccines” meeting explores how vaccine development is being innovated in order to create more efficacious vaccines, such as using Systems Biology or Reverse Vaccinology. The use of adjuvants – their safety and mode of action – will also be discussed, as will DNA vaccines, Toll-Like Receptors, and novel modes of delivery. In addition, how improved vaccines are targeting infectious diseases will be addressed and updated.